Results from a recent trial indicated continuously decreasing risks of all forms of retinal vascular occlusion and retinal vein occlusion for 5 years after treatment.
Aleksandra Rachitskaya, MD, FASRS
Advertisement
Articles by Aleksandra Rachitskaya, MD, FASRS
Expert retina specialists discuss the latest therapies that could reduce the treatment burden and provide superior clinical outcomes in retinal diseases.
Expert retina specialists discuss the latest therapies that could reduce the treatment burden and provide superior clinical outcomes in retinal diseases.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on HCPLive
1
Emerge Phase 3: DT120 Shows Rapid, Durable Relief in MDD
2
Skin of Color Savvy—A New Generation of Dermatology Leadership, With Umayr Shaikh, MPH
3
FAACT's “Food Allergies in the City” Offers Clinicians a Window into Patients' Daily Life
4
Key Clinical Practice Pearls in Atopic Dermatitis, With Elaine Siegfried, MD
5